GGrantIndex
← Search

Shared Resource: Cell Culture Facility

$33,716P30FY2021CANIH

Research Inst Of Fox Chase Can Ctr, Philadelphia PA

Investigators

Linked publications, trials & patents

Paper 39604567Paper 39602533Paper 39554190Paper 39546469Paper 39521739Paper 39514554Paper 39371220Paper 39345610Paper 39343653Paper 39223207Paper 39207123Paper 39189642Paper 39148468Paper 39137728Paper 39072643Paper 39060143Paper 39013784Paper 39003201Paper 38982062Paper 38976159Paper 38963567Paper 38914477Paper 38871720Paper 38865671Paper 38853421Paper 38835516Paper 38815457Paper 38811332Paper 38798370Paper 38766032Paper 38747616Paper 38678525Paper 38659828Paper 38639476Paper 38638131Paper 38600381Paper 38586274Paper 38586042Paper 38559274Paper 38547779Paper 38539515Paper 38464238Paper 38452871Paper 38432028Paper 38421650Paper 38377387Trial NCT04290585Trial NCT03177057Trial NCT02594826Trial NCT02132884Trial NCT02132858Trial NCT02132845Trial NCT02110953Trial NCT02092714Trial NCT02050009Trial NCT01982591Trial NCT01962948Trial NCT01934179Trial NCT01840150Trial NCT01462630Trial NCT01316757Trial NCT01212822Trial NCT00750009Trial NCT00509626Trial NCT00458588Trial NCT00436397Trial NCT00433524Trial NCT00084591Trial NCT00084539Trial NCT00084526Trial NCT00084513Trial NCT00066677Trial NCT00062322Trial NCT00062309Trial NCT00043108Trial NCT00039520Trial NCT00039507Trial NCT00022308Trial NCT00021398Trial NCT00021372Trial NCT00021346Trial NCT00021333Trial NCT00021320Trial NCT00005037Trial NCT00003264Trial NCT00003263Trial NCT00003109Patent 9533040Patent 9182383Patent 9101603Patent 8980258Patent 8685658Patent 8609437Patent 8580263Patent 8329873Patent 7332585Patent 7332580Patent 7129057Patent 6946275Patent 6617427

Abstract

CELLULAR/MOLECULAR ANALYSES SHARED RESOURCE: CELL CULTURE FACILITY (CCF) PROJECT SUMMARY/ABSTRACT The Cell Culture Facility (CCF) serves as a customized pay-for-service facility with the primary goal of providing expertise, technical support, reagents, equipment, liquid nitrogen storage, and training to increase the effectiveness and efficiency of using mammalian cell for FCCC Cancer Center members. The CCF, with the direction of Kerry Campbell, PhD (BCDF) and a staff of 4.5 FTEs offers technical assistance and consultation services in tissue culture techniques, centralized liquid nitrogen banking, mycoplasma screening services, the preparation of custom and standard culture media and supplements, performance testing of fetal bovine serum, cell propagation, and technical support and supplies for mouse embryonic stem (ES) cell transfection and culture. Major efforts by the CCF include carrying out technically challenging techniques, such as the establishment of primary cell cultures from patient or animal tissue samples, hybridoma fusion and cloning services to generate monoclonal antibodies, and culturing and manipulating ES cells to generate genetically manipulated mice. Cell culture technology plays an essential role in modern cancer research, and is used in a diverse array of laboratories as evidenced by the 48 Cancer Center members who used the CCF in calendar year 2014. 95% of service hours logged for specialized cell culture services during 2014 were in support of peer-review funded research. 68 Cancer Center members from all 5 Research Programs used the CCF in the period 2011-2014. Importantly, the Facility supplies the FCCC community with valuable on-site expertise for a host of established cell culture protocols to assure quality control, expert consultation in the design and evaluation of experiments, training in cell culture methodologies, high quality culture media and supplements at reduced costs, bulk purchase pricing of high quality performance-tested fetal bovine serum, and the capacity to deliver personalized assistance and custom-prepared culture supplies in a timely and cost- effective manner. Purchasing serum in bulk via the CCF saves FCCC $81,000 per year. Campbell has directed the CCF for 15 years. Campbell's leadership prompted an institutional investment of $243,000 for new equipment and renovation/expansion of the CCF. This renovation has significantly improved physical infrastructure by localizing all operations in one central location, improving operational efficiencies for the Facility staff, purchasing new and upgraded equipment, and providing a cleaner working environment to perform tissue culture under sterile conditions. The CCF is advised by a dedicated Facility Advisory Committee (FAC) that meets annually. Recommendations from the FAC are directed to a governing Facility Parent Oversight Committee that serves to ensure that the CCF continues to have the necessary resources to provide the highest quality cell culture services for Cancer Center members. Demand for services is expected to increase in the next cycle of the CCSG due to plans to recruit in all 5 Programs, and new demand from Cancer Center members at TU. Additionally, CCF services are available to investigators at the Wistar Institute.

View original record on NIH RePORTER →